How to read clinical trials
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In facilisis, nunc vel facilisis ullamcorper, urna quam dictum.
How to read clinical trialsStudy Overview
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizumab, with or without chemotherapy. The primary goals are to assess safety and efficacy of the treatments.
 |
national trial reference number | NCT06731907 |
 |
Merck Protocol ID | MK-3475-01G |
 |
Conditions |
Non-Small Cell Lung Cancer
|
 |
Age Range | 18+ |
 |
Sex | All |
 |
Trial Phase | 2 |
 |
Start Date End Date |
[03-30-2025] [03-12-2032] |
Study Details
Patient Participation
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Non-Small Cell Lung Cancer
Trial Phase 2
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial Locations (1)
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
Commitment to patient safety
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In facilisis, nunc vel facilisis ullamcorper, urna quam dictum m
Commitment to patient safetyFrequently Asked Questions
About the Study
Before you agree to participate, the study team will review all aspects of the research study with you. If you decide to take part, you will be given a document called an Informed Consent Form that provides, in writing, the research study s purpose, assessments, procedures, potential benefits
and risks, and precautions. You will have the opportunity to ask questions and decide if participating is right for you.
Privacy, Stopping Participation, Costs, and Permission
The study team respects and protects your privacy and will not share your information except as required by law and will store your personal
information with codes that do not identify you. The Informed Consent Form (completed by you prior to participation) will provide more
information about how your privacy will be maintained.
Yes, your participation in the research study is entirely voluntary and you may withdraw for any reason, at any time. If you do decide to withdraw
early, you will be asked to notify the study team before doing so. You will also be asked to return to the study site at least once to complete a final
visit and return any unused study drugs.
No, you will receive the study drugs at no cost. You will also get all study related medical tests at no cost.
No, your doctor does not have to give permission for you to participate. However, either you or the study doctor, with your permission, may
contact your personal doctor to discuss your participation before you begin and keep your doctor up to date about your progress.
About Research Studies
A research study, also known as a clinical trial, tries to answer questions about how medicines work in the people who take them. Researchers run
studies to test whether an investigational study drug is safe and effective. These research studies may help doctors find new ways to help prevent,
detect, or treat health problems.
Participant safety is the priority. There are rules in place to help protect the rights, safety, and well being of people who volunteer for research
studies. These rules are put in place to make sure research studies follow strict scientific and ethical guidelines.
Before a research study can begin, a review board or ethics committee must review the research study. In the US, this group is called an IRB or
Institutional Review Board. An IRB is made up of doctors, scientists, and other members of the community.
Only people who meet all eligibility criteria for a research study may take part. The study team at the site you select will review your medical
history and current medical status against the eligibility criteria. They will determine whether you are eligible to participate. You may also be asked
to provide information from your medical records to help the study team determine whether you may be eligible.
An investigational study drug is a drug that hasn t yet been approved for use in the general public. In order to be approved, the investigational
study drug must be tested in research studies to see if it is safe and effective for treating the target disease in certain groups of people.
If you are eligible and choose to participate, the study staff will be available to answer any questions you may have.
For more answers to your questions visit: https://www.merckclinicaltrials.com/faq/
What can you do next?
Submit your information
Interested in this research study? Submit your information to be contacted to see if you may qualify.
The information you provide will be kept confidential.
Get StartedDiscuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Contact our Trial Information Center
To learn more, call 1-888-577-8839.